Revel Pharmaceuticals
Revel Pharmaceuticals is a pre-clinical biotech developing enzyme-based therapeutics that target and reverse age-related molecular damage (crystal accumulation, crosslinks, glycation) in structural tissue, with pipeline indications spanning neurodegeneration, heart disease, arthritis, skin aging, and gout.
- Company typePrivate
- Founded2022
- HeadquartersSan Francisco, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Revel Pharmaceuticals does
Revel Pharmaceuticals is a privately held, pre-clinical biotechnology company developing enzyme-based therapeutics intended to reverse age-related molecular damage in the body's structural tissue. Founded in 2022 and headquartered in San Francisco, the company operates with a small team (1-10 employees) led by co-founder and CEO Aaron Cravens, PhD, and co-founder and Scientific Advisor Jason Crawford, PhD. The company's central thesis is that approximately 70% of the body consists of structural tissue (collagen, elastin, extracellular matrix) where the majority of age-related damage accumulates, and that conventional medicines primarily target the remaining ~30% (cells). Revel seeks to address this gap by developing enzymes capable of recognizing and reversing distinct molecular forms of damage—specifically crystal accumulation, crosslink damage, and glycation damage—across indications including neurodegeneration, heart disease, arthritis, skin aging, and gout.
The company's core technology is an enzyme discovery and engineering platform that screens millions of natural enzyme variants against real substrates, rather than computational predictions, to identify rare therapeutic hits and engineer them into drug candidates. This platform generates candidates that feed into the company's Targeted Enzymatic Repair pipeline. To date, no commercial products exist, and the company does not hold disclosed patents or trademarks. The scientific advisory board includes domain experts such as Dr. Vincent Monnier, Dr. Gjalt Huisman, and Dr. Jennifer Cochran (also an Independent Board Member), providing expertise in enzyme therapeutics and aging research.
Revel's business model is built around future pharmaceutical licensing, partnerships, or direct commercialization upon clinical and regulatory success. Currently, the company is funded primarily by a March 2022 $8.4 million seed round led by Kizoo Technology Capital (with participation from Starbloom Capital and LongGame VC), supplemented by NIH SBIR grant funding and a smaller October 2025 exempt offering of $83,567 via Gaingels. As a pre-clinical stage company with no revenue, distribution, or commercial partnerships, all value creation is contingent on advancing the enzyme pipeline toward IND-enabling studies and clinical trials.
Revel Pharmaceuticals firmographics
Firmographics- Name
- Revel Pharmaceuticals
- Legal name
- Gaingels Revel Pharmaceuticals LLC
- Website
- https://revelpharmaceuticals.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Revel Pharmaceuticals is a pre-clinical biotech developing enzyme-based therapeutics that target and reverse age-related molecular damage (crystal accumulation, crosslinks, glycation) in structural tissue, with pipeline indications spanning neurodegeneration, heart disease, arthritis, skin aging, and gout.
- Ownership category
- akta.pro rank
Revel Pharmaceuticals industry classification
Industry- akta.pro primary industry
- Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)
- akta.pro secondary industries
- Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB), Therapeutic Enzymes & Enzyme Replacement Therapies (ERT) (HLAAAAAK)
Keywords
Where Revel Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Revel Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Enzyme Therapeutics Development: Pre-revenue biotech developing enzyme therapies targeting age-related diseases including neurodegeneration, heart disease, arthritis, skin aging, and gout. Revenue will be generated through pharmaceutical licensing, partnerships, or product sales upon clinical and regulatory success.
Go-to-market motion1 record
Marketing channels1 record
Revel Pharmaceuticals product offering
Product offeringCore offering
Revel Pharmaceuticals is a pre-clinical biotechnology company developing enzyme-based therapeutics intended to reverse age-related molecular damage in structural tissue (collagen, elastin, extracellular matrix). Its core offering combines a proprietary Enzyme Discovery Platform — which screens millions of natural enzyme variants against real substrates to identify and engineer drug candidates — with a Targeted Enzymatic Repair pipeline targeting crystal accumulation, crosslink damage, and glycation damage for conditions including neurodegeneration, heart disease, arthritis, skin aging, and gout.
Product overview
Revel Pharmaceuticals is a biotechnology company developing a unified platform of enzyme-based therapies aimed at reversing aging by repairing molecular damage in the extracellular scaffold. The company's core offering is the Enzyme Discovery Platform, which screens natural enzyme variants to identify therapeutic candidates, combined with Targeted Enzymatic Repair products that address specific age-related damage types (crystal accumulation, crosslink damage, and glycation damage). The platform and pipeline products are integrated: the platform generates the enzyme candidates that advance into the therapeutic product pipeline.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- Enzyme pipeline advancing toward clinical trials for reversing age-related damage
Companies that use Revel Pharmaceuticals
Customer profileSegments1 record
Ideal customer profiles1 record
Revel Pharmaceuticals technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Revel Pharmaceuticals partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights4 records
Revel Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Turn Biotechnologies: Early-stage longevity biotech developing therapies to repair age-related cellular damage using mRNA-based reprogramming. Highly comparable to Revel as a small, venture-backed aging-reversal biotech with multiple disease targets.
- Unity Biotechnology: Clinical-stage biotech developing senolytic therapies that clear senescent cells to treat age-related diseases including musculoskeletal and ophthalmologic conditions. Comparable to Revel as a public longevity biotech targeting specific age-related indications, though with a different (senolytic) mechanism.
- Life Biosciences: Private longevity biotech developing therapeutics that target fundamental mechanisms of aging across multiple indications. Directly comparable to Revel as a multi-program, venture-backed aging biotech.
- BioAge Labs: Clinical-stage biotech identifying drug targets through AI-driven analysis of human aging biology, with pipeline programs in obesity and neuromuscular indications. Comparable to Revel as a venture-backed aging biotech, though with a more discovery-stage AI approach.
Broad incumbents
- Altos Labs: Well-capitalized longevity biotech ($3B+ raised) pursuing cellular reprogramming to reverse aging and age-related diseases. Compares to Revel as a broad player in the aging-reversal space, though with a different (cellular, not enzymatic) mechanism and vastly greater resources.
- Calico Life Sciences: Alphabet-backed R&D organization focused on aging biology and age-related disease. Broad incumbent in the same longevity space as Revel, with substantially more capital and a focus on basic biology and small-molecule approaches.
Emerging players
- Insilico Medicine: AI-driven drug discovery company with a significant focus on aging and age-related diseases, including fibrosis and oncology. Comparable to Revel as an emerging longevity/drug-discovery player, though differentiated by AI-first approach versus Revel's wet-lab enzyme screening.
- NewLimit: Private biotech founded by Coinbase CEO Brian Armstrong, focused on epigenetic reprogramming therapies to reverse aging. Emerging player comparable to Revel as a venture-backed aging biotech pursuing novel rejuvenation mechanisms.
- Loyal for Dogs: Loyal subsidiary developing pharmaceutical products to extend dog lifespan and healthspan, with a translational path to human aging therapeutics. Adjacent peer to Revel — also pursuing drug-based interventions against aging biology, though in veterinary-first development.
- Gordian Biotechnology: Preclinical biotech using an in vivo screening platform to identify therapeutics for age-related and chronic diseases. Comparable to Revel as an early-stage, platform-based biotech applying systematic screening to aging biology, though with an in vivo rather than enzymatic approach.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
Revel Pharmaceuticals social profiles
Digital presenceRevel Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Revel Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles9 records
Revel Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds2 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Revel Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Revel Pharmaceuticals
What does Revel Pharmaceuticals do?
Revel Pharmaceuticals is a pre-clinical biotechnology company developing enzyme-based therapeutics intended to reverse age-related molecular damage in structural tissue (collagen, elastin, extracellular matrix). Its core offering combines a proprietary Enzyme Discovery Platform — which screens millions of natural enzyme variants against real substrates to identify and engineer drug candidates — with a Targeted Enzymatic Repair pipeline targeting crystal accumulation, crosslink damage, and glycation damage for conditions including neurodegeneration, heart disease, arthritis, skin aging, and gout.
Is Revel Pharmaceuticals a public or private company?
Revel Pharmaceuticals is a private company. It is currently operating.
When was Revel Pharmaceuticals founded?
Revel Pharmaceuticals was founded in 2022. It employs 1 to 10 people.
Where is Revel Pharmaceuticals based?
Revel Pharmaceuticals is headquartered in San Francisco, United States, in the North America region.
How does Revel Pharmaceuticals make money?
One revenue line is on record: enzyme Therapeutics Development.
Who are Revel Pharmaceuticals's main competitors?
Direct peers on record are Turn Biotechnologies, Unity Biotechnology, Life Biosciences and BioAge Labs. Broad incumbents are Altos Labs and Calico Life Sciences. Emerging players are Insilico Medicine, NewLimit, Loyal for Dogs and Gordian Biotechnology.
Does Revel Pharmaceuticals have an API?
No public API is recorded for Revel Pharmaceuticals.
What industry is Revel Pharmaceuticals in?
Its primary akta.pro industry code is HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization), with a secondary code of HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors).